Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 16, 1997

View Archived Issues

Tokyo Tanabe discloses beta3-adrenoceptor agonists

Protein tyrosine kinase inhibitors from Kyowa Hakko

Novel antitumor agents from Kyowa Hakko

Prokinetic agents disclosed by Zeria

SKB reports new delta-receptor agonists/antagonists

New antibiotics from BTG

Chiroscience investigates MMP/TNF inhibitors

Abbott discloses antibacterial tiacumicin derivatives

New antihistamines in the pipeline at HMR

Biochemie reports new cephalosporins

Ortho reports analgesic drug candidates

Johns Hopkins investigators report new growth factor

Neuroprotective agent described by Taisho

Schering-Plough develops dual PAF and histamine antagonist

Fujisawa characterizes novel antidementia agent

Paracelsian signs CRADA with NCI

Avonex update presented

Long-acting calcium channel blocker proves effective in post-MI patients

Pharmacia & Upjohn's Estring now available on U.S. market

First launch for AccuSite

New approvals for Zagam

Fluasterone enters phase I as breast cancer prevention agent

Integrilin scheduled for review

Generic version of Monistat-7 approved by FDA

February review for Medco's vasodilator combination

Approval sought for Androtest-SL

Genelabs completes first pivotal trial on SLE Rx

Cel-Sci receives award for TB diagnostic

ArQule and Signal expand drug discovery agreement

Lilly and TheraTech drug collaboration

New impotence Rx now available in U.S.

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...